These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8889711)

  • 1. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Sievers TM; Kubak BM; Wong-Beringer A
    J Antimicrob Chemother; 1996 Sep; 38(3):333-47. PubMed ID: 8889711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
    Souza LC; Campa A
    J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Herbrecht R; Letscher V
    J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
    Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
    Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B intralipid formulation: stability and particle size.
    Ranchère JY; Latour JF; Fuhrmann C; Lagallarde C; Loreuil F
    J Antimicrob Chemother; 1996 Jun; 37(6):1165-9. PubMed ID: 8836819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
    Steimbach LM; Tonin FS; Virtuoso S; Borba HH; Sanches AC; Wiens A; Fernandez-Llimós F; Pontarolo R
    Mycoses; 2017 Mar; 60(3):146-154. PubMed ID: 27878878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
    Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
    BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
    Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
    Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice.
    Gadebusch HH; Pansy F; Klepner C; Schwind R
    J Infect Dis; 1976 Nov; 134(5):423-7. PubMed ID: 792355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of an Intralipid formulation of nystatin in murine systemic candidiasis.
    Semis R; Mendlovic S; Polacheck I; Segal E
    Int J Antimicrob Agents; 2011 Oct; 38(4):336-40. PubMed ID: 21839619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines in mice treated with amphotericin B-intralipid.
    Shadkchan Y; Keisari Y; Segal E
    Med Mycol; 2004 Apr; 42(2):123-8. PubMed ID: 15124865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.
    Cacciapuoti A; Gurnani M; Halpern J; Norris C; Patel R; Loebenberg D
    Antimicrob Agents Chemother; 2005 Feb; 49(2):638-42. PubMed ID: 15673745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralipid in prophylaxis of amphotericin B nephrotoxicity.
    Vita E; Schroeder DJ
    Ann Pharmacother; 1994 Oct; 28(10):1182-3. PubMed ID: 7841575
    [No Abstract]   [Full Text] [Related]  

  • 14. Antifungal activity against Candida albicans of starch Pickering emulsion with thymol or amphotericin B in suspension and calcium alginate films.
    Cossu A; Wang MS; Chaudhari A; Nitin N
    Int J Pharm; 2015 Sep; 493(1-2):233-42. PubMed ID: 26231107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.
    Johansen HK; Gotzsche PC
    Cochrane Database Syst Rev; 2000; (3):CD000969. PubMed ID: 10908480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient.
    Nicol AJ; Cassidy MJ; Michalowsky K; Kahn D
    Nephron; 1996; 73(2):312-3. PubMed ID: 8773363
    [No Abstract]   [Full Text] [Related]  

  • 18. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
    Brogden RN; Goa KL; Coukell AJ
    Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of liposomal amphotericin B against four species of Candida biofilms in an experimental mouse model of intravascular catheter infection.
    Fujimoto K; Takemoto K
    J Infect Chemother; 2018 Dec; 24(12):958-964. PubMed ID: 30209024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice.
    Rabinovich S; Shaw BD; Bryant T; Donta ST
    J Infect Dis; 1974 Jul; 130(1):28-31. PubMed ID: 4601179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.